Journals / Psikiyatride Güncel Yaklaşımlar / 2016 / Cilt: 8 - Sayı: 1

P-glycoprotein and its Role in Treatment Resistance

P-glikoprotein ve Tedaviye Dirençteki Rolü

Pages
19–31
Publication Date
2016-01-23
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the role of p-glycoprotein on drug pharmacokinetics and bioavailability of psychiatric drugs are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polypharmacy which has often used to increase efficacy of treatment and to prevent resistance in psychiatry may lead to pharmacokinetic and pharmacodynamic drug interactions.
📊
Key Findings & Data:The interactions of some drugs with p-glycoprotein which is a carrier protein, can lead to a decrease in the bioavailability of these drugs and reduction in passage through the blood-brain barrier.
💡
Conclusion & Impact:In this review, the role of p-glycoprotein on drug pharmacokinetics and bioavailability of psychiatric drugs are discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:P-glikoprotein · çoklu ilaç direnci · kan-beyin bariyeri

Abstract

Polypharmacy which has often used to increase efficacy of treatment and to prevent resistance in psychiatry may lead to pharmacokinetic and pharmacodynamic drug interactions. One of the intensively studied topic in recent years to clarify the mechanism of drug interactions, in the pharmacokinetic area is p-glycoprotein related drug-drug and drug-food interactions. The interactions of some drugs with p-glycoprotein which is a carrier protein, can lead to a decrease in the bioavailability of these drugs and reduction in passage through the blood-brain barrier. In this review, the role of p-glycoprotein on drug pharmacokinetics and bioavailability of psychiatric drugs are discussed.

Özet

Psikiyatride tedavi etkinliğini artırmak ve direnci önlemek amacıyla sıklıkla uygulanan polifarmasi, farmakokinetik ve farmakodinamik ilaç etkileşimlerine neden olabilmektedir. İlaç etkileşim mekanizmalarının aydınlatılması amacıyla, farmakokinetik alanında son yıllarda üzerinde yoğun olarak çalışılan bir konu p-glikoproteine bağlı ilaç-ilaç ve ilaç-besin etkileşmeleridir. Bazı ilaçların bir taşıyıcı protein olan p-glikoprotein ile olan etkileşmeleri, bu ilaçların biyoyararlanımlarında düşüşe ve kan-beyin bariyerinden geçişlerinde azalmaya yol açabilmektedir. Bu derlemede, p-glikoproteinin ilaç farmakokinetiğinde ve psikiyatrik ilaçların biyoyararlanımındaki rolü tartışılmıştır.

🔖

Cite This Article

GÜL, İ. G., ERYILMAZ, G., KARAMUSTAFALIOĞLU, K. O. (2016). P-glycoprotein and its Role in Treatment Resistance. Psikiyatride Güncel Yaklaşımlar, Cilt: 8 - Sayı: 1, 19–31. https://ajindex.com/articles/229866

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Aszalos A (2007) Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today, 12:838-843.
  2. Balayssac, D., Authier, N., Cayre A., Coudore, F (2005) Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett, 156:319-329. Bartels AL, de Klerk OL, Kortekaas R, de Vries JJ, Leenders KL (2010) 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Curr Top Med Chem, 10:1775-1784.
  3. Clarke G, O'Mahony SM, Cryan JF, Dinan TG (2009) Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter? Hum Psychopharmacol, 24:217-223.
  4. Dean, M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res, 11(7):1156-1166.
  5. De Klerk OL, Bosker FJ, Luurtsema G, Nolte IM, Dierckx RA, Den Boer JA et al. (2011) The role of P-glycoprotein in psychiatric disorders: a trustful guard of the brain? Cent Nerv Syst Agents Med Chem, 11:197-209.
  6. De Klerk OL, Willemsen AT, Bosker FJ, Bartels AL, Hendrikse NH, den Boer JA et al. (2010) Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P- glycoprotein function. Psychiatry Res, 183:151-156.
  7. De Klerk OL, Willemsen AT, Roosink M, Bartels AL, Hendrikse NH, Bosker FJ et al. (2009) Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int J Neuropsychopharmacol, 12:895-904.
  8. De Luca V, Mındo E, Trakalo J, Wong GW, Kennedy JL (2003) Investigation of polymorphism in the MDR1 gene and antidepressant-inducced mania. Pharmacogenomics J, 3:297-299.
  9. Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W (2000) Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse, 36:66-74.
  10. Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC (2004) P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate, 59:77-90.
  11. Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther, 38:69-74.
  12. Fromm MF (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv R